CNBC Television

Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs

Name: Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs
Uploaded: 2025-11-05T14:20:45Z
Description: Novo Nordisk CEO Mike Doustdar joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's bid for obesity biotech company Metsera, negotiations with the Trump administration to sell some of its obesity drugs to consumers at a lower rate, expanding the use of obesity drug,

11/5/2025, 2:20:45 PM

View channel Watch on YouTube

Economic Summary

Novo Nordisk (NVO) reported lowered full-year profit and revenue guidance this morning, reflecting short-term financial pressure but not altering its strategic focus on obesity therapies.
There is an active acquisition battle for Medsara (private), with Novo raising offers (reported around $9–10 billion) to secure complementary assets; this could push M&A valuations higher in the obesity therapeutics space and increase competition between NVO and Pfizer (PFE).
The broader obesity market is large: Novo highlighted roughly 100 million U.S. patients with obesity but only a few million currently receiving therapy, implying significant long-term revenue and access opportunities if pricing and distribution improve (including discussions about programs like TrumpRx).
Medsara's lead asset entering phase 3 and development of longer-duration dosing (monthly) could materially enhance product portfolios for acquirers and shift competitive dynamics among obesity drugmakers.

Bullish

Novo Nordisk is a market leader in obesity drugs and seeks to expand access via acquisitions.
Medsara has a lead asset entering phase 3 with promising monthly-dosing potential, complementing existing pipelines.
Pfizer's entry into the obesity space increases validation and potential competitive partnerships or consolidation.

Bearish

Novo Nordisk (NVO) cut its full-year profit and revenue forecast, signaling near-term operational pressures.
A bidding war for Medsara raises acquisition cost and deal uncertainty, risking dilution or overpayment.
Regulatory and access negotiations (e.g., TrumpRx discussions) remain unresolved, creating policy and distribution uncertainty.

Bullish tickers

NVOMEDSARAPFE

Bearish tickers

NVOMEDSARA

NVO

Bullish

Market leader in obesity drugs with strong internal pipeline and willingness to acquire complementary assets to expand patient access.

Bearish

Lowered full-year profit and revenue forecast and potential stock pressure; facing expensive bidding for Medsara.

PFE

Bullish

Has pursued Medsara and obtained regulatory approvals on prior deals, signaling strategic entry into obesity market.

Bearish

Late entrant to obesity therapeutics historically and may lose Medsara to a higher bidder; deal uncertainty persists.

MEDSARA

Bullish

Small company with a lead asset entering phase 3 and promising monthly-dosing candidates that complement larger portfolios.

Bearish

Target of competing bids and a potential merger-termination dispute; acquisition outcome uncertain.

People mentioned

Mike DudstarkJoeDonald Trump